A recently published Serial cross-sectional analysis of National Health and Nutrition Examination Survey data has been published suggesting that overall blood pressure control in adults with hypertension over the last 4 years has declined.Why is this? What tips can the pharmacist and prescriber use to improve control? Can these professionals work together to improve BP control? Can we survive under pressure?Additional Resources/References: Muntner P, Hardy ST, Fine LJ, et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324(12):1190–1200. doi:10.1001/jama.2020.14545This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The LoDoCo2 Trial suggested that colchicine may improve outcomes in patients with cardiovascular disease. Can a 3,000 year old drug still be a miracle?Additional Resources/References: Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Aug 31. doi: 10.1056/NEJMoa2021372. Epub ahead of print. PMID: 32865380.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The fear of a "Twindemic," an influenza and COVID-19, double pandemic is starting to rise. But what does the data say about this fear? Is the US in double trouble with BOGO viral infections?This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Updated osteoporosis guidelines have arrived from the American Association of Clinical Endocrinology. The AACE guidelines include different recommendations from the 2017 National Osteoporosis Foundation guidelines, primarily due to new anabolic agents. Learn about a newly created a new patient risk stratified category, the role of bisphosphonates, and how to approach patient care.Additional Resources/References:FRAX calculator: US version https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9; AACE osteoporosis guidelineshttps://www.aace.com/disease-stateresources/reproductive-and-gonad/clinical-practiceguidelines-recent-news-and-updatesThis episode is accredited for CPE. Subscribe at CEimpact(https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Medications are only 10 percent of total US healthcare expenditure, yet remain a focus of healthcare costs. In this Gamechangers episode, Geoff Wall and guest, Jake Galdo, will discuss two articles evaluating generic utilization on Medicare costs. By giving up brands, can we lower costs?Additional Resource/Reference: https://jamanetwork.com/journals/jamacardiology/article-abstract/2770174 and https://jamanetwork.com/journals/jama/fullarticle/2697695This episode is accredited for CPE. Subscribe at CEimpact https://www.ceimpact.com/pharmacist  and claim your CE today! See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Antibiotics are a risk factor for Clostridium difficile infections. Combining a review of the 2017 Infectious Diseases Society of America and recent literature for prophylactic therapies, learn how to care for patients between a rock and a hard place.Additional Resource/Reference: https://learn.ceimpact.com/library/group/12/course/2313 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The TAILOR-PCI Trial evaluates the outcomes between genotype-guided P2Y12 inhibitor selection versus conventional prescribing on ischemic outcomes. Listen to Geoff Wall and guest, Jake Galdo, discuss the role of pharmacogenomics in patient care.Additional Resource/Reference:https://jamanetwork.com/journals/jama/article-abstract/2769725 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

New guidelines from American College of Physicians suggest that first-line treatment of non-low back musculoskeletal injuries are topical therapies. Topical non-steroidal anti-inflammatory drugs, like diclofenac, are available as over-the-counter products in the US. Learn about the preferred route of care when treating pain.Additional Resource/Reference: https://www.acpjournals.org/doi/10.7326/M19-3602 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Community Pharmacies are vital members of neighborhoods and the healthcare community. A major social determinant of health is access to healthcare - both providers and medications. Recently, Berenbrok and colleagues published research that showed community pharmacies are visited almost twice as much compared to primary care providers by Medicare beneficiaries annually. Guest Jake Galdo will be joining our host Geoff Wall to discuss how community pharmacists provide care.Additional Resource/Reference: https://jamanetwork.com/journals/jamanetworkopen/fullarUcle/2768247 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The COVID-19 pandemic continues to rage on worldwide. Data surrounding the treatment of patients with COVID-19 respiratory failure is moving at lightning pace, so for this week's episode we will discuss the latest (as of 8/13/20) information surrounding two modalities for COVID-19 treatment: convalescent plasma and tocilizumab. This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram